GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » 5-Year EBITDA Growth Rate

Hua Medicine (HKSE:02552) 5-Year EBITDA Growth Rate : 18.70% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine 5-Year EBITDA Growth Rate?

Hua Medicine's EBITDA per Share for the six months ended in Dec. 2024 was HK$-0.09.

During the past 3 years, the average EBITDA Per Share Growth Rate was 15.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hua Medicine was 68.10% per year. The lowest was -14.00% per year. And the median was 20.70% per year.


Competitive Comparison of Hua Medicine's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hua Medicine's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hua Medicine's 5-Year EBITDA Growth Rate falls into.


;
;

Hua Medicine 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Hua Medicine  (HKSE:02552) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Hua Medicine 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hua Medicine's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hua Medicine Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Hong Jane Xingfang 2202 Interest of your spouse
Chen Li 2101 Beneficial owner
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner

Hua Medicine Headlines

No Headlines